原发前列腺癌中预存的前列腺癌去势抵抗样细胞促进激素治疗耐药
研究从新鲜人前列腺癌标本(原发腺癌、局部复发去势抵抗性前列腺癌(CRPC)及转移性CRPC)分离上皮细胞,用单细胞RNA测序识别 destined 成为CRPC-腺癌或小细胞神经内分泌癌(SCNC)的亚群。在23226个上皮细胞中揭示促进疾病进展的动态转录重编程,并在激素初治早期前列腺癌中发现小比例高可塑性CRPC样细胞,其与生化复发和远处转移相关且独立于临床特征。作者结论认为CRPC样细胞在前列腺癌早期即存在,CRPC与SCNC表型应在疾病早期被靶向。
要点
- 早期激素初治前列腺癌中即存在小比例高可塑性CRPC样细胞。
- CRPC样细胞与生化复发和远处转移相关,且独立于临床特征。
- 向去势抵抗的进展源于亚型特异性谱系可塑性和预存神经内分泌及CRPC样细胞的克隆扩增。
核心结论
- CRPC样细胞在前列腺癌早期即存在,并非仅是雄激素剥夺治疗期间获得性进化选择的结果。
- 致死性CRPC和SCNC表型应在前列腺癌患者疾病病程更早期被靶向。
研究设计与样本
- 从新鲜人前列腺癌病例分离上皮细胞,包括原发腺癌、局部复发CRPC和转移性CRPC。
- 利用单细胞RNA测序识别 destined 成为CRPC-腺癌或小细胞神经内分泌癌(SCNC)的亚群。
- 使用免疫组化和大型公共基因组数据队列验证亚群特异性进展。
主要发现
- 在23226个上皮细胞中揭示促进疾病进展的动态转录重编程。
- 在激素初治早期前列腺癌中发现小比例高可塑性CRPC样细胞。
- CRPC样细胞与生化复发和远处转移相关,独立于临床特征。
- 向去势抵抗的进展源于亚型特异性谱系可塑性和早期前列腺癌中预存神经内分泌及CRPC样细胞的克隆扩增。
临床怎么用
- 作者认为,肿瘤中预存神经内分泌和CRPC样细胞增多的患者可能对ADT快速耐药,可能需要积极的早期干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hormonal therapy targeting the androgen receptor inhibits prostate cancer (PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC). OBJECTIVE: To understand the mechanisms by which subclones within early PCa develop into CRPC. DESIGN, SETTING, AND PARTICIPANTS: We isolated epithelial cells from fresh human PCa cases, including primary adenocarcinoma, locally recurrent CRPC, and metastatic CRPC, and utilized single-cell RNA sequencing to identify subpopulations destined to become either CRPC-adeno or small cell neuroendocrine carcinoma (SCNC). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We revealed dynamic transcriptional reprogramming that promotes disease progression among 23226 epithelial cells using single-cell RNA sequencing, and validated subset-specific progression using immunohistochemistry and large cohorts of publically available genomic data. RESULTS AND LIMITATIONS: We identified a small fraction of highly plastic CRPC-like cells in hormone-naïve early PCa and demonstrated its correlation with biochemical recurrence and distant metastasis, independent of clinical characteristics. We show that progression toward castration resistance was initiated from subtype-specific lineage plasticity and clonal expansion of pre-existing neuroendocrine and CRPC-like cells in early PCa. CONCLUSIONS: CRPC-like cells are present early in the development of PCa and are not exclusively the result of acquired evolutionary selection during androgen deprivation therapy. The lethal CRPC and SCNC phenotypes should be targeted earlier in the disease course of patients with PCa. PATIENT SUMMARY: Here, we report the presence of pre-existing castration-resistant prostate cancer (CRPC)-like cells in primary prostate cancer, which represents a novel castration-resistant mechanism different from the adaptation mechanism after androgen deprivation therapy (ADT). Patients whose tumors harbor increased pre-existing neuroendocrine and CRPC-like cells may become rapidly resistant to ADT and may require aggressive early intervention.
引用
- Cheng Q, Butler W, Zhou Y, et al. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. 2022. PMID: 35058087. doi:10.1016/j.eururo.2021.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。